HONOLULU — A patient’s sputum microbiome may serve as a biomarker for the outcome of antibiotic treatment for nontuberculosis mycobacterial pulmonary disease, according to research presented at the CHEST Annual Meeting.
Microbial diversity at baseline appeared higher among those who reached a microbiologic cure vs. those resistant to treatment, and both sets of patients had different species composition with time and continued treatment, according to researchers.
“While there exists a scoring system for predicting the mortality of patients with nontuberculosis mycobacterial